For the quarter ending 2025-09-30, KURA had $13,339K increase in cash & cash equivalents over the period. -$83,194K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -74,116 | -123,551 |
| Share-based compensation expense | 10,965 | 14,791 |
| Depreciation expense | 164 | 465 |
| Non-cash interest expense | 141 | 271 |
| Amortization of premium and accretion of discounts on short-term investments, net | 1,924 | 5,182 |
| Contract liabilities | 15,664 | 23,763 |
| Accounts payable and accrued expenses | 12,716 | 2,098 |
| Other long-term liabilities | 297 | 628 |
| Receivable from contracts with collaborators | 31,362 | 2,514 |
| Prepaid expenses and other current assets | 10,289 | 8,551 |
| Operating lease right-of-use and other long-term assets | 2,883 | 2,922 |
| Net cash used in operating activities | -80,627 | -100,704 |
| Maturities of short-term investments | 235,032 | 342,596 |
| Purchases of short-term investments | 138,499 | 383,314 |
| Purchases of property and equipment | 2,567 | 1,750 |
| Net cash provided by (used in) investing activities | 93,966 | -42,468 |
| Proceeds from issuance of stock under equity plans | 0 | 658 |
| Net cash provided by financing activities | 0 | 658 |
| Net increase (decrease) in cash and cash equivalents | 13,339 | -142,514 |
| Cash and cash equivalents at beginning of period | 224,462 | - |
| Cash and cash equivalents at end of period | 95,287 | - |
Kura Oncology, Inc. (KURA)
Kura Oncology, Inc. (KURA)